A nanomedicine stack built from the molecule outward
Every BBlueBio programme starts with the barrier a therapy has to cross. The carrier, the targeting ligand and the analytical method are then engineered together rather than assembled from off-the-shelf parts.
Ionizable carriers tuned for endosomal escape
Most delivery failures happen after uptake: the payload is swallowed by the endosome and degraded before it reaches the cytosol. Our ionizable lipid series shifts protonation state precisely in that pH window, releasing cargo where it stays active.
- pKa tuned between 6.2 and 6.6 for tissue-specific release
- PEG shedding kinetics matched to circulation half-life targets
- Compatible with mRNA, siRNA, ASO, peptide and small-molecule payloads
- Cryo-TEM and SAXS characterisation on every development lot
- Particle size range
- 12–80 nm
- Polydispersity index
- < 0.09
- Encapsulation efficiency
- 96.4%
- Batch scale
- 5 mL → 50 L
- Storage stability
- 30 days @ 4 °C
- Endotoxin
- < 0.25 EU/mL
Diagnostics that keep pace with the therapy
Precision delivery is only measurable with precision detection, so we develop the assay alongside the carrier.
Femtomolar detection
Cadmium-free quantum dots paired with affibody capture layers resolve biomarker concentrations three orders of magnitude below standard ELISA.
Multiplexed readout
Twelve distinct emission channels on a single chip let a panel be read in one 9-minute run without cross-talk correction.
Field-ready optics
The reader runs on a 12 V supply and tolerates 15–40 °C ambient, so assays travel to the sample instead of the reverse.
Scale-up without reformulation
Continuous-flow production means the clinical lot is made by the same physics as the bench batch — not a redesign under deadline.
- 1
Formulation
Design-of-experiments across 40+ lipid ratios, executed by liquid handlers with automated DLS feedback.
- 2
Continuous mixing
Staggered herringbone micromixers hold residence time within ±2%, keeping size distribution identical at every scale.
- 3
Purification
Tangential-flow filtration and buffer exchange with in-line conductivity and UV monitoring.
- 4
Release testing
Size, zeta potential, RNA integrity, potency and sterility — documented to ICH Q2(R2).
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programs with pharma, biotech and academic groups — from target selection through GMP supply.